Biologic therapies target type 2 inflammatory mediators, such as immunoglobulin E (IgE), interleukin-4 (IL-4) and interleukin-5 (IL-5), and thymic stromal lymphopoietin (TSLP), thereby reducing asthma exacerbations and OCS use while improving QOL and lung function [7,8]. This evidence concerns the gene IL4 and asthma.